Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK):: LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,3-dibromophenyl) propenamide].

被引：0

作者：

Uckun, FM ^{[1
]}

Sudbeck, EA ^{[1
]}

Zheng, YG ^{[1
]}

Mahajan, S ^{[1
]}

Ghosh, S ^{[1
]}

机构：

[1] Hughes Inst, St Paul, MN 55113 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1999年 / 217卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

147-MEDI

引用

页码：U1199 / U1199

页数：1

共 8 条

[1] Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]
Mahajan, S
Ghosh, S
Sudbeck, EA
Zheng, YG
Downs, S
Hupke, M
Uckun, FM
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (14) : 9587 - 9599
[2] A novel anti-leukemic agent selectively targeting Bruton's tyrosine kinase (BTK):: LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)-propenamide].
Ghosh, S
Mahajan, S
Mao, C
Sudbeck, E
Zheng, Y
Uckun, FM
BLOOD, 1998, 92 (10) : 602A - 602A
[3] The anti-leukemic Bruton's tyrosine kinase inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism
Uckun, FM
Vassilev, A
Bartell, S
Zheng, YG
Mahajan, S
Tibbles, HE
LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1569 - 1577
[4] Preclinical toxicity and pharmacokinetics of the Brutons tyrosine kinase-targeting anti-leukemic drug candidate, α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13)
Uckun, Fatih M.
Tibbles, Heather
Venkatachalam, Taracad
DuMez, Darin
Erbeck, Douglas
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (01): : 31 - 46
[5] In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase
Uckun, FM
Zheng, YG
Cetkovic-Cvrlje, M
Vassilev, A
Lisowski, E
Waurzyniak, B
Chen, H
Carpenter, R
Chen, CL
CLINICAL CANCER RESEARCH, 2002, 8 (05) : 1224 - 1233
[6] Prevention of fata thromboembolism in mice by selectively targeting BTK and TEC kinases in platelets with α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13).
Tibbles, HE
Vassilev, AO
Wendorf, H
Zhu, D
Bartell, S
Lorenz, D
Waurzyniak, B
Zheng, Y
Mahajan, S
Uckun, FM
BLOOD, 2000, 96 (11) : 275A - 275A
[7] Large-scale synthesis of GMP grade α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate
DuMez, Darin
Venkatachalam, Taracad K.
Uckun, Fatih M.
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (03): : 155 - 163
[8] Rational design and synthesis of α-cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl]propenamide as a potent and specific inhibitor of the EGF-receptor tyrosine kinase in human breast cancer cells.
Ghosh, S
Zheng, YG
Jun, X
Narla, RK
Mahajan, S
Navara, C
Mao, C
Sudbeck, EA
Uckun, FM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1172 - U1172

← 1 →